Feed Symbols: PLX

  Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the most-searched-for stocks on Benzinga Pro in the month of April.

Here's a roundup of top developments in the biotech space over the last 24 hours:

Protalix BioTherapeutics Inc (NYSE:PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., have announced topline data from the BALANCE Phase…

Protalix BioTherapeutics Inc (AMEX:PLX) shares are surging Monday after the company said its Phase 3 trial for the treatment of Fabry disease met its primary endpoint. Fabry disease is an inherited disease resulting in progressive accumulation of abnormal deposits of a fatty substance in blood vessel walls throughout a person's body.

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_03312022_PLX_Vandermosten.pdf

  Protalix BioTherapeutics (AMEX:PLX) reported its Q4 earnings results on Thursday, March 31, 2022 at 06:50 AM. Here's what investors need to know about the announcement.

  Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.

Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A, have 

Study achieved key objectives for safety, efficacy and pharmacokinetics After completion of the study, all patients enrolled in an extension study Treatment with PRX-102 provided coverage for the entire four‑week period